Postmastectomy Breast Reconstruction in Patients with Non-Metastatic Breast Cancer: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline
- PMID: 40558300
- PMCID: PMC12191886
- DOI: 10.3390/curroncol32060357
Postmastectomy Breast Reconstruction in Patients with Non-Metastatic Breast Cancer: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline
Abstract
Several postmastectomy breast reconstruction techniques and procedures have been implemented, although with limited evaluation of benefits and adverse effects. We conducted a systematic review on the plane and timing of reconstruction, and on the use of nipple-sparing mastectomy, acellular dermal matrix, and autologous fat grafting as the evidence base for an updated clinical practice guideline on breast reconstruction for Ontario Health (Cancer Care Ontario). Both immediate and delayed reconstruction may be considered, with preferred timing depending on factors such as patient preferences, type of mastectomy, skin perfusion, comorbidities, pre-mastectomy breast size, and desired reconstructive breast size. Immediate reconstruction may provide greater psychological or quality of life benefits. In patients who are candidates for skin-sparing mastectomy and without clinical, radiological, and pathological indications of nipple-areolar complex involvement, nipple-sparing mastectomy is recommended provided it is technically feasible and acceptable aesthetic results can be achieved. Surgical factors including incision location are important to reduce necrosis by preserving blood supply and to minimize nerve damage. There is a role for both prepectoral and subpectoral implants; risks and benefits will vary, and decisions should be made during consultation between the patient and surgeons. In patients who are suitable candidates for implant reconstruction and have adequate mastectomy flap thickness and vascularity, prepectoral implants should be considered. Acellular dermal matrix (ADM) has led to an increased use of prepectoral reconstruction. ADM should not be used in case of poor mastectomy flap perfusion/ischemia that would otherwise be considered unsuitable for prepectoral reconstruction. Care should be taken in the selection and handling of acellular dermal matrix (ADM) to minimize risks of infection and seroma. Limited data from small studies suggest that prepectoral reconstruction without ADM may be feasible in some patients. Autologous fat grafting is recommended as a treatment for contour irregularities, rippling following implant-based reconstruction, and to improve tissue quality of the mastectomy flap after radiotherapy.
Keywords: acellular dermal matrix; autologous fat grafting; autologous reconstruction; breast implants; breast reconstruction; delayed reconstruction; immediate reconstruction; nipple-sparing mastectomy; prepectoral; subpectoral.
Conflict of interest statement
CS reported receiving honoraria for chairing or moderating two speaker series on updates in oncological advancements to regional surgical, medical, and radiation oncologists. F.C.W. was Surgical Oncology Provincial Lead, which is a programme of the sponsor, Ontario Health (Cancer Care Ontario). The other authors declare no conflicts of interest. The funder approved the research questions and project plan prior to commencement of the systematic review. The sponsor had no role in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
Similar articles
-
Postmastectomy Breast Reconstruction in Patients with Non-Metastatic Breast Cancer: A Systematic Review.Curr Oncol. 2025 Apr 16;32(4):231. doi: 10.3390/curroncol32040231. Curr Oncol. 2025. PMID: 40277787 Free PMC article.
-
Do we need acellular dermal matrix in prepectoral breast reconstruction? A systematic review and meta-analysis.J Plast Reconstr Aesthet Surg. 2023 Nov;86:251-260. doi: 10.1016/j.bjps.2023.09.042. Epub 2023 Sep 21. J Plast Reconstr Aesthet Surg. 2023. PMID: 37793198
-
Different types of implants for reconstructive breast surgery.Cochrane Database Syst Rev. 2016 May 16;2016(5):CD010895. doi: 10.1002/14651858.CD010895.pub2. Cochrane Database Syst Rev. 2016. PMID: 27182693 Free PMC article.
-
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340. Health Technol Assess. 2006. PMID: 16959170
-
Skin-sparing mastectomy for the treatment of breast cancer.Cochrane Database Syst Rev. 2023 Mar 27;3(3):CD010993. doi: 10.1002/14651858.CD010993.pub2. Cochrane Database Syst Rev. 2023. PMID: 36972145 Free PMC article.
References
-
- Winters Z.E., Benson J.R., Pusic A.L. A systematic review of the clinical evidence to guide treatment recommendations in breast reconstruction based on patient- reported outcome measures and health-related quality of life. Ann. Surg. 2010;252:929–942. doi: 10.1097/SLA.0b013e3181e623db. - DOI - PubMed
-
- Pusic A.L., Klassen A.F., Snell L., Cano S.J., McCarthy C., Scott A., Cemal Y., Rubin L.R., Cordeiro P.G. Measuring and managing patient expectations for breast reconstruction: Impact on quality of life and patient satisfaction. Expert Rev. Pharmacoecon. Outcomes Res. 2012;12:149–158. doi: 10.1586/erp.11.105. - DOI - PMC - PubMed
-
- Kronowitz S.J. A systematic review of the clinical evidence to guide treatment recommendations in breast reconstruction based on patient-reported outcome measures and health-related quality of life: Winters ZE, Benson JR, Pusic AL (Univ of Bristol, UK; Univ of Cambridge, UK; Memorial Sloan-Kettering Cancer Ctr, NY) Ann Surg 252:929-942, 2010. Breast Dis. 2011;22:420–422. doi: 10.1016/j.breastdis.2011.10.042. - DOI - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical